profit from every $100 of sales.
$0$100
Evolent Health
$4.71+2.84% today
-5.0% in 1 year
1-year low $2.171-year high $6.19
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Evolent Health sold, what it kept, and what it did with the cash.
Sales went from $1.35 billion in 2022 to $1.88 billion in 2025, with -$535 million of profit last year.
SalesProfit
Evolent Health handed back more cash to shareholders than it generated last year.
Buybacks $40M$11M
Free cash flow 2025$5M
Bought back its own shares$40M
Paid as dividends$11M
Cash vs. debt$152M vs. $990M
Evolent Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Evolent Health | No profit yet | ||
 GE HealthCare Technologies | 18.2× · Fair price | ||
 Tempus AI | No profit yet | ||
 BrightSpring Health Services | 72.2× · Very expensive | ||
 HealthEquity | 39.2× · Expensive |
AI analysis
An AI analyst reads Evolent Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,352 | 1,964 | 2,555 | 1,876 | |
| 317 | 460 | 367 | 400 | |
| -20 | -21 | -14 | -20 | |
| 21 | -25 | 80 | -361 | |
| -19 | -113 | -62 | -535 | |
| -0.20 | -1.28 | -0.81 | -5.07 | |
| 23.4% | 23.4% | 14.4% | 21.3% | |
| -1.5% | -1.1% | -0.6% | -1.1% | |
| -1.4% | -5.8% | -2.4% | -28.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,817 | 2,680 | 2,544 | 1,899 |
| Cash | 188 | 193 | 104 | 152 |
| Total debt | 476 | 645 | 714 | 990 |
| Total liabilities | 958 | 1,613 | 1,543 | 1,484 |
| 859 | 1,068 | 1,001 | 415 | |
| 94 | 111 | 115 | 114 | |
| -2.8% | -6.8% | -1.8% | -26.8% | |
| -2.2% | -10.6% | -6.2% | -128.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | 143 | 19 | 39 | |
| 38 | 29 | 25 | 34 | |
| -50 | 114 | -6 | 5 | |
| Dividends paid | 15 | 19 | 20 | 11 |
| – | 0 | 0 | 40 | |
| 34 | 41 | 40 | 40 |
Valuation
- –
- 34.3×
- –
- 1.1×
- 0.3×
- 112.0×
- –
- 0.9%
- -100.3%
- 0.0%
Profitability
- 21.3%
- -1.1%
- -28.5%
- 5.4%
- -1.1%
- -10.7%
- -77.9%
- -26.4%
- -1.1%
- –
Growth
- +11.5%
- –
- +177.6%
- –
- +7.3%
Financial health
- –
- 2.49
- 52.4%
- -0.3×
- 1.32
- 1.32
- 1.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 948
Bottom 20%of 871
Top 49%of 868
Bottom 47%of 985
What analysts expect
- Average price target
- $6.38
- Range
- $3.50 – $10.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.02 | -0.05 | +60.0% |
| Feb 24, 2026 | 0.08 | 0.06 | +33.3% |
| Nov 6, 2025 | 0.05 | 0.10 | −50.0% |
| Aug 7, 2025 | -0.10 | 0.09 | −211.1% |
| May 8, 2025 | 0.06 | 0.09 | −33.3% |
| Feb 20, 2025 | -0.02 | 0.38 | −105.3% |
| Nov 7, 2024 | 0.04 | 0.30 | −86.7% |
| Aug 8, 2024 | 0.30 | 0.21 | +42.9% |
News
Evolent Health, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
11No pass
Benjamin Graham
38No pass
Philip Fisher
19No pass
Peter Lynch
25No pass
Joel Greenblatt
0No pass
Charlie Munger
8No pass
Terry Smith
13No pass
Questions about Evolent Health
Is Evolent Health a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Evolent Health AI analysis
What does Evolent Health do?
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. It is in Medical - Healthcare Information Services.
Does Evolent Health pay a dividend?
Yes. In 2025 it paid out $11.1 million in dividends.
Is Evolent Health stock halal?
No. Evolent Health does not pass our halal screen: its debt is 186% of its market value, at or above the 33% limit. How we check
How has Evolent Health stock done over the past year?
Down 5.0% over the past twelve months, to $4.71. It traded between $2.17 and $6.19 and is 23.9% below its high.
Who are Evolent Health's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, Tempus AI, BrightSpring Health Services and HealthEquity. The peers table on this page compares their profit, growth and price with Evolent Health's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.